Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies
Edward Meier,1 Abhijit Narvekar,2 Ganesh R Iyer,2 Harvey B DuBiner,3 Apinya Vutikullird,4 David Wirta,5 Kenneth Sall61Apex Eye, Mason, OH, 2Alcon Research Ltd., Fort Worth, TX, 3Clayton Eye Center, Morrow, GA, 4WCCT Global, Cypress, 5Eye Research Foundation, Newport Beach, 6Sall Eye Researc...
Enregistré dans:
Auteurs principaux: | Meier E, Narvekar A, Iyer GR, DuBiner HB, Vutikullird A, Wirta D, Sall K |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2017
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/f5dce38dc0a34beb94abeb38f871ad08 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis
par: McLaurin E, et autres
Publié: (2017) -
Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment
par: Mizoguchi T, et autres
Publié: (2017) -
Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model
par: Torkildsen G, et autres
Publié: (2015) -
Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model
par: Meier EJ, et autres
Publié: (2018) -
Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
par: Malhotra RP, et autres
Publié: (2019)